### ðŸ«€ Cardioâ€‘Oncology: Trastuzumab Cardiotoxicity

#### âœ… True Statements
1. **Trastuzumab**, a monoclonal antibody used to treat **human epidermal growth factor receptorÂ 2 (HER2)â€“positive cancers**, can cause **reversible left ventricular (LV) systolic dysfunction**, resulting in clinical heart failure symptoms in approximately **3â€¯%â€¯â€“â€¯7â€¯%** of treated patients.  
2. The risk of **trastuzumabâ€‘induced cardiotoxicity** is higher in **patients older than 50â€¯years** and in those who receive **concomitant anthracycline chemotherapy**.  
3. Patients receiving **trastuzumab** should undergo serial **transthoracic echocardiography (TTE)** to monitor **left ventricular ejection fraction (LVEF)** and detect early, asymptomatic cardiac dysfunction.  
4. Expert consensus recommends **holding trastuzumab temporarily** when **LVEF falls by >15â€¯percentage points from baseline** or **drops by â‰¥10â€¯percentage points to a value <50â€¯%**.  
5. **Trastuzumab therapy may be resumed** once **LV function normalizes** after drug withdrawal, because the cardiotoxicity is usually **reversible**.  
6. Patients whose **LVEF remains â‰¥50â€¯%** during **trastuzumab** treatment can generally **continue therapy** without evidence of longâ€‘term cardiac injury.  
7. **TTE** is sufficient for both **initial detection** and **followâ€‘up assessment** of **trastuzumabâ€‘related cardiac dysfunction**; **cardiac catheterization is not required** for routine monitoring.  

#### ðŸ’¬ Extra
1. Unlike anthracycline cardiotoxicity, trastuzumabâ€‘related LV dysfunction is **not dose dependent** and typically improves within weeks to months after stopping the drug.  
2. Ageâ€‘related decline in cardiac reserve and prior anthracycline exposure create a vulnerable myocardial substrate that amplifies trastuzumab toxicity.  
3. The optimal frequency of TTE surveillance during trastuzumab therapy is individualized, but many centers perform imaging **every 3Â months** in highâ€‘risk patients.  
4. The LVEF threshold for interruption of therapy is derived from prospective trials and expert guidelines to balance cancer control with cardiac safety.  
5. Restoration of normal LVEF allows oncologists to **reâ€‘initiate trastuzumab** and maintain oncologic efficacy without compromising longâ€‘term cardiac outcomes.  
6. Observational studies report **no increase in heart failure events or mortality** when LVEF remains at or above 50â€¯% during trastuzumab therapy.  
7. Nonâ€‘invasive imaging avoids procedural risks and provides additional data (for example, **global longitudinal strain**) that may detect subclinical dysfunction earlier than LVEF alone.  

#### ðŸ”· Tags
#CardioOncology #Cardiology #AmbulatoryCare #Trastuzumab #Cardiotoxicity #LeftVentricularDysfunction

#### ðŸ“™ Reference
PlanaÂ JC, GalderisiÂ M, BaracÂ A, etâ€¯al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Journal of the American Society of Echocardiography*. 2014;27:911â€‘939. PMID:â€¯25172399 doi:10.1016/j.echo.2014.07.012

#### ðŸ†” Question ID
CVMCQ24042

#### ðŸ•’ Last Updated
FebruaryÂ 2025

#### ðŸ“– Related Text
MKSAPÂ 19: Cardiovascular Medicineâ€¯â€”â€¯Cardiotoxicity of Chemotherapy

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **Chemotherapyâ€‘associated cardiotoxicity** includes both **reversible myocardial injury** (for example, with **trastuzumab**) and **doseâ€‘dependent, irreversible injury** (for example, with **anthracyclines**).  
2. Before starting potentially cardiotoxic chemotherapy, clinicians should **optimize traditional cardiovascular risk factors** and identify **patients at greatest longâ€‘term cardiac risk**.  
3. **Acute anthracycline cardiotoxicity** occurs in **<1â€¯%** of patients, may manifest as **arrhythmias, heart block, myocarditis, pericarditis, or heart failure**, and is usually **reversible**.  
4. **Chronic progressive anthracycline cardiomyopathy** is typically **irreversible**, presents as **dilated cardiomyopathy**, and is most strongly linked to **doxorubicin** exposure, although **epirubicin** and **idarubicin** can also be implicated.  
5. The incidence of **heart failure** rises to **â‰ˆ26â€¯%** when the **cumulative anthracycline dose reaches 550â€¯mg/mÂ²**, and toxicity may not become apparent until **10â€¯â€“â€¯20â€¯years** after treatment.  
6. **Dexrazoxane**, an **ironâ€‘chelating agent**, reduces **anthracyclineâ€‘induced cardiotoxicity** and should be considered in **highâ€‘risk patients**.  
7. Riskâ€‘reduction strategies for anthracycline therapy include **continuous infusion** rather than bolus dosing and use of **liposomal doxorubicin formulations**.  
8. **Targeted cancer therapies** such as **trastuzumab**, **multitargeted tyrosine kinase inhibitors** (for example, **sunitinib**), and **antiâ€‘vascular endothelial growth factor antibodies** (for example, **bevacizumab**) frequently cause **reversible left ventricular dysfunction or hypertension**.  
9. **Sunitinib** is associated with **new or worsened hypertension in up to 50â€¯%** of patients and **left ventricular ejection fraction (LVEF) reduction in up to 15â€¯%**, effects that are generally **reversible with early recognition and management**.  
10. Baseline and surveillance testing for chemotherapy cardiotoxicity should include **transthoracic echocardiography (TTE)**; measuring **global longitudinal strain (GLS)** can detect **early, subclinical left ventricular dysfunction** more sensitively than ejection fraction alone.  
11. For patients receiving **anthracyclines**, it is reasonable to repeat TTE at a **cumulative dose of 250â€¯mg/mÂ²** and **before each additional dose** in those with **preâ€‘existing LV dysfunction** or when higher cumulative doses are planned.  
12. During **trastuzumab** therapy, the drug should be **withheld temporarily** if **LVEF falls by >15â€¯percentage points from baseline** or **drops â‰¥10â€¯percentage points to <50â€¯%**.  
13. A **relative GLS decline >15â€¯%** is considered **subclinical LV dysfunction** and should prompt **cardiology consultation**.  
14. Surveillance for **sunitinib cardiotoxicity** should include baseline **Nâ€‘terminal proâ€“Bâ€‘type natriuretic peptide (NTâ€‘proBNP)** measurement and **LVEF assessment at baseline, 1â€¯month, and every 3â€¯months** thereafter.  
15. In patients who develop **clinical signs or symptoms of cardiac dysfunction** during chemotherapy, evaluation with **cardiac biomarkers (troponin, NTâ€‘proBNP)** and **TTE including GLS** is recommended, and treatment follows **standard heart failure guidelines** while decisions about continuing chemotherapy are **individualized**.
16. **High-dose anthracycline chemotherapy** (â‰¥250 mg/mÂ² doxorubicin or â‰¥600 mg/mÂ² epirubicin) is a recognized factor that increases a cancer survivorâ€™s long-term cardiovascular risk.
17. **Combined anthracycline + trastuzumab therapy** confers a higher likelihood of delayed cardiomyopathy than either agent used alone.
18. Thoracic **radiation of â‰¥30Â Gy that includes the heart** in the treatment field is an independent predictor of late-onset cardiovascular disease.
19. **Alkylating agents** (for example, cyclophosphamide and ifosfamide) can precipitate chemotherapy-related **left ventricular (LV) systolic dysfunction**.
20. Anti-metabolite therapy with **5â€‘fluorouracil or capecitabine** is strongly associated with **chemotherapy-induced myocardial ischemia**.
21. **Bevacizumab**, an antiâ€‘vascular endothelial growth factor monoclonal antibody, may produce **hypertension** *and* **ischemia** during treatment.
22. **Thalidomide**, an angiogenesis inhibitor, is linked to **venous thromboembolism** and can also provoke **bradycardia or atrioventricular block**.
23. **Oxaliplatin** therapy can **prolong the QT interval** and trigger **torsades de pointes** ventricular tachyarrhythmia.
24. The tyrosine kinase inhibitor **vandetanib** likewise carries a recognized risk of **marked QT prolongation** leading to torsades de pointes.
25. **Doxorubicin** exposure has been associated with **monomorphic ventricular tachycardia** in addition to its well-known cardiomyopathy.
26. **Paclitaxel** infusion may cause **transient bradycardia or atrioventricular nodal block** during administration.
27. **Cisplatin and cyclophosphamide** have been implicated in chemotherapy-related **atrial fibrillation** even in patients without prior structural heart disease.

#### ðŸ’¬ Extra
3. These acute effects typically occur during or shortly after anthracycline infusion and often resolve with cessation of the drug and supportive care.  
5. Doseâ€‘dependent anthracycline cardiomyopathy underscores the importance of lifetime dose limits and longâ€‘term cardiac surveillance in survivors.  
9. Early interruption of **sunitinib** and initiation of antihypertensive or heartâ€‘failure therapy can hasten recovery of blood pressure and LVEF.  
12. Observational studies show that resuming **trastuzumab** after LVEF recovery does not appear to increase longâ€‘term cardiac risk.
16. The â‰¥250â€¯mg/mÂ² anthracycline threshold helps identify patients who should receive baseline and serial echocardiography for early cardiotoxicity detection.
17. Synergistic cardiotoxicity from combined DNAâ€‘topoisomeraseâ€¯II inhibition and HER2 blockade underlies the high risk with concurrent anthracyclineâ€‘trastuzumab therapy.
18. Radiationâ€‘induced heart disease may manifest years later as coronary artery disease, valvular stenosis, constrictive pericarditis, or LV dysfunction.
19. Cyclophosphamideâ€‘related cardiomyopathy often appears within days of highâ€‘dose therapy used for boneâ€‘marrow conditioning.
20. 5â€‘Fluorouracilâ€“induced coronary vasospasm can mimic an acute coronary syndrome and typically resolves with nitrates and calciumâ€‘channel blockers.
21. Bevacizumabâ€‘related hypertension is usually manageable with standard antihypertensive agents; ischemia is less common but warrants prompt evaluation.
22. Because of its thrombotic risk, thalidomide therapy often requires prophylactic lowâ€‘dose aspirin or anticoagulation in highâ€‘risk patients.
23. Monitoring electrolytes and obtaining baseline and periodic electrocardiograms are recommended during oxaliplatin therapy.
24. Vandetanibâ€™s label recommends ECG monitoring and correction of hypokalemia or hypomagnesemia before and during therapy.
25. Ventricular arrhythmias with doxorubicin typically signify significant myocardial injury and may necessitate treatment interruption.
#### ðŸ”· Tags
#CardioOncology #AnthracyclineCardiotoxicity #Trastuzumab #TyrosineKinaseInhibitors #VEGFInhibitors #Echocardiography #GlobalLongitudinalStrain #NTproBNP #HeartFailurePrevention

---

#### ðŸ—¾ Supplemental Tables

<!-- Cancer Therapyâ€“Associated Factors Table -->
<table>
  <caption><strong>Cancer Therapyâ€“Associated Factors That Increase Longâ€‘Term Cardiovascular Risk</strong></caption>
  <tbody>
    <tr><td>Anthracycline or trastuzumab in patients with multiple cardiovascular risk factors</td></tr>
    <tr><td>Highâ€‘dose anthracycline (â‰¥250&nbsp;mg/mÂ² doxorubicin or â‰¥600&nbsp;mg/mÂ² epirubicin)</td></tr>
    <tr><td>Combination anthracycline and trastuzumab</td></tr>
    <tr><td>Combination anthracycline and radiation</td></tr>
    <tr><td>Radiation of â‰¥30&nbsp;Gy with the heart in the treatment field</td></tr>
  </tbody>
</table>

<!-- Cardiovascular Toxic Effects of Chemotherapeutic Agents Table -->
<table>
  <caption><strong>Cardiovascular Toxic Effects of Chemotherapeutic Agents</strong></caption>
  <thead>
    <tr>
      <th>Toxicity</th>
      <th>Class</th>
      <th>Drugs</th>
    </tr>
  </thead>
  <tbody>
    <tr><td>Left ventricular dysfunction</td><td>Alkylating agents</td><td>Cyclophosphamide, ifosfamide</td></tr>
    <tr><td>Left ventricular dysfunction</td><td>Anthracyclines</td><td>Doxorubicin, epirubicin, idarubicin</td></tr>
    <tr><td>Left ventricular dysfunction</td><td>Antimicrotubular agents</td><td>Paclitaxel, docetaxel</td></tr>
    <tr><td>Left ventricular dysfunction</td><td>Monoclonal antibody</td><td>Trastuzumab</td></tr>
    <tr><td>Left ventricular dysfunction</td><td>Proteasome inhibitor</td><td>Bortezomib, carfilzomib</td></tr>
    <tr><td>Left ventricular dysfunction</td><td>Tyrosine kinase inhibitor</td><td>Sunitinib</td></tr>
    <tr><td>Ischemia</td><td>Antimetabolites</td><td>5â€‘Fluorouracil, capecitabine</td></tr>
    <tr><td>Ischemia</td><td>Antimicrotubular agents</td><td>Paclitaxel, docetaxel</td></tr>
    <tr><td>Ischemia</td><td>Monoclonal antibody</td><td>Bevacizumab</td></tr>
    <tr><td>Ischemia</td><td>Tyrosine kinase inhibitors</td><td>Erlotinib, sorafenib</td></tr>
    <tr><td>Hypertension</td><td>Monoclonal antibody</td><td>Bevacizumab</td></tr>
    <tr><td>Hypertension</td><td>Tyrosine kinase inhibitors</td><td>Sorafenib, sunitinib</td></tr>
    <tr><td>Venous thromboembolism</td><td>Alkylating agent</td><td>Cisplatin</td></tr>
    <tr><td>Venous thromboembolism</td><td>Angiogenesis inhibitor</td><td>Thalidomide</td></tr>
    <tr><td>Venous thromboembolism</td><td>Tyrosine kinase inhibitor</td><td>Erlotinib</td></tr>
    <tr><td>Bradycardia / atrioventricular block</td><td>Angiogenesis inhibitor</td><td>Thalidomide</td></tr>
    <tr><td>Bradycardia / atrioventricular block</td><td>Antimicrotubular agent</td><td>Paclitaxel</td></tr>
    <tr><td>QT prolongation resulting in torsades de pointes</td><td>Alkylating agent</td><td>Oxaliplatin</td></tr>
    <tr><td>QT prolongation resulting in torsades de pointes</td><td>Anthracycline</td><td>Aclarubicin</td></tr>
    <tr><td>QT prolongation resulting in torsades de pointes</td><td>Miscellaneous</td><td>Arsenic</td></tr>
    <tr><td>QT prolongation resulting in torsades de pointes</td><td>Tyrosine kinase inhibitor</td><td>Vandetanib</td></tr>
    <tr><td>Atrial fibrillation</td><td>Alkylating agents</td><td>Cisplatin, cyclophosphamide, ifosfamide</td></tr>
    <tr><td>Atrial fibrillation</td><td>Anthracyclines</td><td>Doxorubicin, aclacinomycinÂ A, mitoxantrone</td></tr>
    <tr><td>Atrial fibrillation</td><td>Antimetabolites</td><td>5â€‘Fluorouracil, leucovorin</td></tr>
    <tr><td>Atrial fibrillation</td><td>Histone deacetylase inhibitor</td><td>Belinostat</td></tr>
    <tr><td>Atrial fibrillation</td><td>Microtubule agents</td><td>Paclitaxel, docetaxel, gemcitabine</td></tr>
    <tr><td>Atrial fibrillation</td><td>Monoclonal antibodies</td><td>Trastuzumab, etaracizumab</td></tr>
    <tr><td>Atrial fibrillation</td><td>Tyrosine kinase inhibitors</td><td>Cetuximab, sunitinib, sorafenib, ibrutinib</td></tr>
    <tr><td>Monomorphic ventricular tachycardia</td><td>Anthracyclines</td><td>Doxorubicin</td></tr>
    <tr><td>Monomorphic ventricular tachycardia</td><td>Antimetabolite</td><td>5â€‘Fluorouracil</td></tr>
    <tr><td>Monomorphic ventricular tachycardia</td><td>Miscellaneous</td><td>Arsenic</td></tr>
    <tr><td>Monomorphic ventricular tachycardia</td><td>Monoclonal antibodies</td><td>Nivolumab, trastuzumab</td></tr>
  </tbody>
</table>
<p><em>Information fromÂ TisdaleÂ JE, ChungÂ MK, CampbellÂ KB, <i>etâ€¯al</i>; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drugâ€‘induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142:e214â€‘e233. doi:10.1161/CIR.0000000000000905</em></p>

